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Abstract. Age and Alzheimer’s disease (AD) share some common features such as cognitive impairments, memory loss,
metabolic disturbances, bioenergetic deficits, and inflammation. Yet little is known on how systematic shifts in metabolic
networks depend on age and AD. In this work, we investigated the global metabolomic alterations in non-transgenic (NTg)
and triple-transgenic (3xTg-AD) mouse brain hippocampus as a function of age by using untargeted Ultrahigh Performance
Liquid Chromatography-tandem Mass Spectroscopy (UPLC-MS/MS). We observed common metabolic patterns with aging
in both NTg and 3xTg-AD brains involved in energy-generating pathways, fatty acids oxidation, glutamate, and sphingolipid
metabolism. We found age-related downregulation of metabolites from reactions in glycolysis that consumed ATP and in
the TCA cycle, especially at NAD+/NADH-dependent redox sites, where age- and AD-associated limitations in the free
NADH may alter reactions. Conversely, metabolites increased in glycolytic reactions in which ATP is produced. With age,
inputs to the TCA cycle were increased including fatty acid -oxidation and glutamine. Overall age- and AD-related changes
were > 2-fold when comparing the declines of upstream metabolites of NAD+/NADH-dependent reactions to the increases
of downstream metabolites (p = 10−5, n = 8 redox reactions). Inflammatory metabolites such as ceramides and sphingosine-1-
phosphate also increased with age. Age-related decreases in glutamate, GABA, and sphingolipid were seen which worsened
with AD genetic load in 3xTg-AD brains, possibly contributing to synaptic, learning- and memory-related deficits. The data
support the novel hypothesis that age- and AD-associated metabolic shifts respond to NAD(P)+/NAD(P)H redox-dependent
reactions, which may contribute to decreased energetic capacity.
Keywords: Alzheimer’s disease, aging, citric acid cycle, dehydrogenase, energy metabolism, fatty acids, glycolysis,
hippocampus, NAD, oxidation-reduction
INTRODUCTION
Alzheimer’s disease (AD) is a neurodegenera-
tive disease characterized by extracellular amyloid-
(A) plaque accumulation, intracellular neurofibril-
lary tangles, metabolic disturbances [1], oxidative
stress [2], inflammation [3], autophagic [4] and
bioenergetic deficits [5, 6]. Despite abundant asso-
ciations, based on clinical trials, it is unclear which
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of these are primal. AD affected an estimated 5.7 mil-
lion in America in 2016 and is projected to grow to
13.8 million by 2050 [7]. Age is the greatest risk fac-
tor for neurodegenerative AD. Aging and AD share
some common features including neurodegeneration
[8], metabolic deficits [9–11], bioenergetic deficits
[12], and inflammation [13]. According to the epige-
netic oxidative redox shift theory of aging, age- and
AD-associated sedentary lifestyle promote oxidative
shifts upstream of reactive oxygen species (ROS) to
initiate a vicious cycle of oxidized membrane recep-
tors, signaling molecules, transcription factors, and
epigenetic transcriptional regulators, which further
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impose a metabolic shift away from the mitochondrial
energy supply [14].
“Omics” technologies including genome [15],
epigenome [16], transcriptome [17], proteome [18,
19], and metabolome [20] studies of mice and human
have examined age- and AD-associated changes in
gene and protein expression [21, 22]. Metabolome
studies integrate the effects of expression of the
genome, epigenome, transcriptome, proteome, and
post-translational modulation of activity by the expo-
some to provide a downstream snap shot of regulatory
signaling networks [23]. An age-associated seden-
tary low-energy state is implicated in AD morbidity
and is coincident with observations of metabolic
shifts and decline in glucose uptake with age [11,
24–26]. AD-associated metabolic perturbation was
reported in tryptophan, tyrosine, methionine, purine
in cerebrospinal fluid (CSF) of AD patients (n = 40)
[27], ceramides and sphingomyelins in plasma of
26 AD patients [28] relative to age-matched con-
trols. Significant metabolic disturbances in transgenic
APP/PS1 AD mouse model include essential amino
acids, branched-chain amino acids, neurotransmit-
ter serotonin, phospholipid, and acylcarnitine [29].
Additionally, changes in energy metabolism result in
metabolic shifts in different regions of aging mouse
brains [30, 31]. We specifically studied metabolic
shifts in hippocampal regions of different ages which
are implicated in impaired episodic memory, short-
and long-term memory, spatial memory, and naviga-
tion. Gene expression in 129/C57BL/6 mouse brains
revealed that from 6 to 9 months, almost two-thirds of
the genes relative to energy and amyloid metabolism
were downregulated, whereas in the age-matched
male brains, only 5% genes were altered [32]. In our
work, we extended the studies to global metabolism
gender-differences across the age-span in the hip-
pocampus. Further, since aging increases the risk for
AD incidence, whether the normal age and AD share
some common shifts or signatures in metabolic pro-
files and patterns in brains and if so, which pathways
are most affected are poorly understood. Moreover,
correlations of metabolic shifts in old age of hip-
pocampal brains relative to the AD model brains at
the sites of redox bioenergetics were examined to
strengthen the redox hypothesis of aging.
Interest in metabolic alterations in AD is anchored
by reduced glucose uptake in AD patients. A study of
20 patients with early-onset dementia of Alzheimer
type (DAT) revealed a 50% reduced metabolic rate
of glucose uptake in the brain and significant eleva-
tion of lactate compared to non-demented subjects
[33]. At the end of glycolysis (stage II), pyruvate
is either oxidized to acetyl-CoA for entry into the
TCA cycle or reduced to lactate, dependent on the
redox status of nicotinamide adenine dinucleotide
oxidized/reduced forms (NAD+/NADH). Since this
redox state becomes more oxidized and the NADH
pool declines with age and in AD transgenic mice
[34, 35], we further explored how these age- and AD-
related oxidative shifts in NADH affected metabolic
networks, especially NAD+/NADH-dependent sub-
strates in glycolysis and NADH production in the
TCA cycle. Lactate serves as an alternative energy
supply for neurons during hypoglycemia [36] and
it also functions as a neuroprotective metabolite
[37] via transcriptional activation of brain-derived
neurotrophic factor expression [38]. In addition to
lactate, Ding et al. [24] demonstrated the utiliza-
tion of ketone bodies as an alternative energy supply
during early glucose insufficiency in mouse brain.
Yao et al. [39] proposed that during an energetic
crisis, a compensatory metabolic shift from glycol-
ysis to ketogenic/fatty acid oxidation caused white
matter degradation. Here, we compared the age-
related shifts of metabolomic profiles in both NTg and
triple-transgenic (3xTg-AD) mouse brain hippocam-
pus of both sexes by using ultrahigh performance
liquid chromatography-tandem mass spectroscopy
(UPLC-MS/MS). We observed major age and AD-
associated shifts of metabolic patterns linked to
energy production and NADPH antioxidant inter-
mediates in the pentose phosphate pathway (PPP),
fatty acid metabolism, glutamine and sphingolipid
metabolism. The prospect of correlating age- and
AD- related shifts in metabolic profiles with impaired
brain energy and antioxidant defense offers a novel
way to study the mechanism of AD, diagnose early
stages of AD among aged population with possible
prognostic implications.
MATERIALS AND METHODS
Mouse model
We used LaFerla’s triple transgenic mouse model
of AD (3xTg-AD) with human transgenes APP
(SWE), PS1 (M146V), and Tau (P301L) driven by
the Thy1.2 promoter to mimic the neuropathological
features of AD [40]. Non-transgenic (NTg) C57BL/6
mice (Charles River, San Diego) were used as con-
trols. In each genotype and each gender, five young
(1–3 month), five middle (8–14 month), and five old
(18–23 month) ages of mice were used. All mice
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underwent genotyping before use in experiments. All
experiments involving animals were approved by the
Institutional Animal Care and Use Committee (AUP-
17-65) and performed according to NIH guidelines
and regulations.
Hippocampal tissue collection
Mice were anesthetized by isoflurane vapor with
subsequent collection of whole brains. Hippocampi
and overlaying entorhinal cortex were isolated, fol-
lowed by immediate flash freezing in liquid nitrogen
for 1 min (n = 5 mice /age/genotype/gender). All sam-
ples were stored at –80◦C until shipping to Metabolon
(Durham, NC, USA) on dry ice for metabolomics
analysis. Samples were randomized and coded for
blinding in the repeated ages and genotypes.
Sample preparation
Samples were prepared using the automated
MicroLab STAR system from Hamilton Company.
Several recovery standards were added before tissue
extraction for quality control (QC). Proteins in the
samples were precipitated with methanol under vig-
orous shaking for 2 min (Glen Mills GenoGrinder
2000) followed by centrifugation. The resulting
extract was divided into five aliquots: two for analysis
by two separate reverse-phase (RP)/UPLC-MS/MS
methods with positive ion mode electrospray (ESI),
one with negative ion mode ESI, one for analysis
by HILIC/UPLC-MS/MS with negative ion mode
ESI, and one sample was stored for backup. Sam-
ples were placed briefly on a TurboVap (Zymark)
to remove the organic solvent. Sample extracts were
stored overnight under nitrogen before preparation
for analysis.
Quality control (QC)
Several types of controls were analyzed in con-
cert with the experimental samples: 1) pooled matrix
sample generated by taking a small volume of each
experimental sample, serving as a technical repli-
cate; 2) extracted water sample as process blanks;
3) a cocktail of QC standards that were carefully
chosen not to interfere with the measurement of
endogenous compounds were spiked into each ana-
lyzed sample to monitor instrumental performance
and aided chromatographic alignment. Instrument
variability was determined by calculating the median
relative standard deviation (RSD) for the standards
that were added to each sample before injection into
the mass spec machine. Overall process variability
was determined by calculating the median RSD for
all endogenous metabolites present in 100% of the
pooled matrix samples. The median RSD of instru-
ment variability and total process variability was 4%
and 11% respectively. Experimental samples were
randomized across the platform run with QC samples
spaced evenly among the injections.
Ultrahigh performance liquid chromatography-
tandem mass spectroscopy (UPLC-MS/MS)
All methods utilized a Waters ACQUITY ultra-
performance liquid chromatography (UPLC) and
a Thermo Scientific Q-Exactive high resolu-
tion/accurate mass spectrometer interfaced with a
heated electrospray ionization (HESI-II) source and
Orbitrap mass analyzer operated at 35,000 mass
resolution. The sample extract was dried followed
by reconstitution in solvents compatible to each of
the four methods. Each reconstitution solvent con-
tained a series of standards at fixed concentrations
to ensure injection and chromatographic consis-
tency. For hydrophilic compounds analyzed using
acidic positive ion condition, the extract was gradient
eluted from a C18 column (Water UPLC BEH C18-
2.1 × 100 mm, 1.7m) using water and methanol,
containing 0.05% perfluoropentanoic acid (PFPA)
and 0.1% formic acid (FA). For hydrophobic com-
pounds analyzed using acidic positive ion conditions,
the extract was gradient eluted from the same C18
column using methanol, acetonitrile, water, 0.05%
PFPA and 0.01% FA. Another aliquot was analyzed
using a basic negative ion optimized condition and
a separate dedicated C18 column. The basic extracts
were gradient eluted form the column using methanol
and water, with 6.5 mM ammonium bicarbonate at
pH 8. The fourth aliquot was analyzed via negative
ionization following elution from a HILIC column
(Waters UPLC BEH Amide 2.1 × 150 mm, 1.7m)
with a gradient of water and acetonitrile with 10 mM
ammonium formate, pH 10.8. The scan range covered
70–1000 m/z.
Compound identification, quantification
Compounds were identified by comparison to
library entries of purified standards or recurrent
unknown entities. Biochemical identifications are
based on three criteria: retention index within a
narrow RI window of the proposed identification,
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accurate mass match to the library ± 10 ppm, and
the MS/MS forward and reverse score between the
experimental data and authentic standards.
Metabolite quantification and data normalization
Peaks were quantified using area-under-the-curve.
Each compound was corrected in run-day blocks by
registering the median to equal one (1.00) and nor-
malizing each data point proportionately across all
age, sex and genotype groups. This allowed determi-
nation of relative changes with age, sex, and genotype
as scaled relative intensities for each metabolite.
Statistical analysis
Following log transformation and imputation of
missing values, if any, with the minimum observed
value for each compound, ANOVA contrasts were
used to identify biochemicals that differed signifi-
cantly between experimental groups. Two-way and
three-way ANOVAs were used to identify biochem-
icals of significant interaction and main effects for
experimental parameters of genotype, age and gen-
der. A hierarchical clustering method was applied
to the fatty acids with calculation of Euclidian dis-
tances and clustering by complete-linkage method in
R statistical software.
RESULTS
Overview of global metabolic shifts in aging
and AD mouse brains
We determined the age and AD-associated shifts
in brain metabolomics by unbiased untargeted
UPLC/MS/MS. By methanol extraction of freshly
isolated mouse hippocampus with overlying cortex
(hereafter hippocampus) from NTg and 3xTg-AD
mice of young, middle and old ages, we were able
to detect and identify 567 metabolites including
amino acids, peptides, carbohydrates, energic inter-
mediates and lipids from a wide range of pathways
(Supplementary Table 1). Significance of changes
in metabolites by age, genotype and gender effects
by ANOVA as well as fold change are listed in
Supplementary Table 2). Figure 1 summarizes those
metabolites altered by genotype and age or addition-
ally by gender. Notably, a large 44% of the detected
metabolites were affected by age and 57% by gen-
der. Additionally, 36% differed by genotype. 21%
of the metabolites showed an interaction of geno-
type and age. To explore how much age contributes
to the metabolic shifts in AD, we grouped metabo-
lites into three categories: both genotypes decreased
with age, increased or were discordant as presented in
Venn diagrams (female and male combined) (Fig. 1).
Each circle area is proportional to the total number of
metabolites. The overlapped area in Fig. 1A indicates
proportions of downregulated metabolites in both old
age and AD, accounting for 43% of the NTg and
63% of the 3xTg-AD metabolites. Similarly, Fig. 1B
shows the common upregulated metabolites in both
normal old age and 3xTg-AD mouse brains, consti-
tuting 62% and 54%, respectively. This high level
of coordinate responses in either downregulation or
upregulation (50–60%) suggests age and AD share
common patterns of metabolic shifts. Additionally,
this may indicate old age metabolism increases the
risk for AD incidence. Discordant metabolites shifted
in opposite directions with age in NTg and 3xTg-AD
samples were just 20% of the total (p < 0.05, genders
combined, Fig. 1C). Among these disparate metabo-
lites, 60% of the metabolites decreased in NTg but
increased in 3xTg-AD samples with age (purple cir-
cle, Fig. 1C). 40% of the metabolites were enhanced
in NTg old age but lowered in 3xTg-AD samples
(orange circle, Fig. 1C). These disparate metabolites
distinguished normal aging from AD, and therefore
indicates specific metabolic features involved in the
AD genotype.
Age-related metabolic shift in glycolytic
and pentose phosphate pathway metabolites
To compare low human utilization of glucose to
mouse brain utilization, we examined the glycolytic
pathway with age and AD-genotype in mouse hip-
pocampus and extended the specificity into steps
of the glycolytic pathway and PPP (Fig. 2). As
the glycolysis pathway and the PPP initially con-
sume all the glucose from glucose-6-phosphate,
we determined whether age and AD were asso-
ciated with greater consumption of metabolites
in these pathways. We observed that metabolites
involved in stage I of glycolysis related to ATP con-
sumption, decreased significantly with age of both
genotypes including glucose, glucose 6-phosphate,
fructose 6-phosphate, and dihydroxyacetone phos-
phate (DHAP). The largest decreases were found in
glucose 6-phosphate and fructose-6 phosphate, which
declined 51-52% in NTg and 27–38% in 3xTg-AD
female with similar decreases in male. Given that
glucose only declined 8–12% in female brains and
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Fig. 1. Majority of metabolites that change with age (old relative to young) coordinately respond in both NTg and 3xTg-AD mouse brains
(female and male combined). Three-way ANOVA for genotype, age, and gender identify 121 metabolites affected commonly by both
genotype and age, accounting for 59% of genotype effects and 49% of age main effects. Numbers of biochemicals exhibiting main effects
(p≤ 0.05) and significant interactions. A) metabolites that decreased significantly in both NTg and 3xTg-AD (p < 0.05). The cyan circle area
represents the number of decreases in old NTg mouse brains (136 metabolites in total), similar to the dark green circle for 3xTg-AD mouse
brains (94 total). The overlap area represents the common metabolites that decreased with aging in both NTg and 3xTg-AD. B) significantly
increased metabolites similarly age-related in NTg (p < 0.05; pink circle, 138 in total) and 3xTg-AD (red circle, 160 metabolites total) with a
large overlap area. C) Number of NTg metabolites with significant opposite change with age of in 3xTg-AD mouse brains (p < 0.05; purple
circle NTg decreased; yellow circle NTg increased). Circle areas and overlaps are proportional to the number of metabolites.
less than 9% in male of both genotypes, this may
indicate an age-related increase in consumption by
energy producing steps of glycolysis and/or diversion
into the PPP. The absence of significant age-related
changes in fructose-1,6-bisphosphate levels with sig-
nificant declines in the upstream substrates glucose
6P and fructose 6P and downstream DHAP, could
indicate an increased age-related rate in phosphofruc-
tosekinase 1 (PFK-1) as an important regulatory point
of glycolysis [41].
Following stage 1 of glycolysis, oxidation
by NAD+, transitions into stage II in which
metabolites were elevated with age (Fig. 2). 3-
phosphoglycerate and phosphoenolpyruvate (PEP)
were elevated 63–75% in NTg and 170–180% 3xTg-
AD hippocampus in females with age, while these
metabolites in males rose 114–119% in NTg and
90–91% in 3xTg-AD. This indicates that the input
exceeds the consumption with age in stage II of
glycolysis. By genotype, these metabolites were
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Fig. 2. In glycolysis and the pentose phosphate pathway (PPP), hippocampal metabolites declined with age in reactions in which ATP
was consumed (green circles with green arrows) and metabolites increased in reactions involved in ATP generation (red circle with red
arrows). Intensities of identified metabolites from mass spectrometry in each hippocampal sample were normalized (n = 5 mouse brain
samples/age/genotype/gender). Mean intensity with standard errors in female (left) and male (right) for 3 ages of young, middle and old age.
Two-way ANOVA was used to calculate statistical significance for each metabolite (p < 0.05 indicates significant age effect). Ns indicates
detection but not significantly affected by age; ND, no detectable.
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34–50% higher from 3xTg-AD hippocampi than
NTg.
The other possible pathway that could account for
the age-related decrease in stage I of glycolysis would
be diversion into the PPP (Fig. 2). At the first com-
mitted step in the PPP, we detected higher levels of
6-phosphogluconate in the 3xTg-AD than the age-
matched NTg samples (combined genders, p < 0.05),
although not significantly changed with age. How-
ever, the downstream metabolite ribose 5-phosphate
in the PPP was 36–52% lower from young to old age
of both genotypes and genders (Fig. 2). Age-related
increased metabolic inputs in PPP from glycolysis
with reduced levels in the downstream metabo-
lite of ribose 5-phosphate suggests an age-related
higher consumption of intermediates in PPP to sup-
port NADPH generation for antioxidant defense or
impairments in PPP with age. Ribulose 5-phosphate
and sedoheptulose 7-phosphate in the PPP were not
significantly changed with age. The PPP partially
fluxes back into glycolysis at the points of glyc-
eraldehyde 3-phosphate and fructose 6-phosphate
(also decreased with age). Among the intermediates
of ATP-consumed steps in glycolysis, only fructose
1,6-bisphosphate was found to be not significantly
changed with age in either NTg and 3xTg-AD sam-
ples. In PPP, 6-phosphogluconate levels were 1.6 to
2-fold higher in 3xTg-AD old samples compared to
age-matched NTg for both genders, indicating higher
demand of NADPH in 3xTg-AD hippocampal brains.
The downstream intermediate ribose 5-phosphate
showed remarkably age-dependent declines in both
genotypes. These decrements in metabolites in the
PPP pathway with age suggest a comparatively higher
metabolism of glucose in the PPP for more NADPH
production and antioxidant defense with AD genetic
load.
At the end of stage II of glycolysis, PEP is
metabolized to pyruvate. Pyruvate is at a criti-
cal intersection to either branch to produce lactate
or enter into the TCA cycle after conversion into
acetyl-CoA. Our results showed age-related 30–45%
decreases in pyruvate of both genders for NTg and
50–58% decreases in 3xTg-AD samples (Fig. 2).
This remarkable switch from an age-related increase
in the PEP precursor to an age-related drop in
pyruvate suggests an increased consumption of pyru-
vate with age, a re-direction in metabolic fluxes
either into lactate or acetyl-CoA. A ratio of lac-
tate to pyruvate (lactate/pyruvate) increased with age
in female (Two-way ANOVA for age and geno-
type F(2,29) = 14, p < 0.001) and male (Two-way
ANOVA F(2,29) = 12, p < 0.001). Compared to the
young age, the lactate/pyruvate ratio in old-age brains
increased 34–52% in NTg and 131–134% in 3xTg-
AD samples of both genders. With age, the 30–50%
drop in pyruvate of both genotypes and genders
was not propagated to lactate levels (<10% shifts
with age), suggesting a balance between produc-
tion and utilization of lactate or removal from the
brain into the blood. The decreased levels of pyru-
vate suggest more output to branches of lactate or the
TCA cycle. The lactate/pyruvate ratio can be regu-
lated by the NAD/NADH ratio [42]. Metabolic flux
experiments are needed for a definitive conclusion
of an age-related decline in ATP production from
glycolysis.
Age-related increased inputs to the TCA cycle
with decreased cycle metabolites
Increased fatty acids and β-oxidation
To further explore if the age-related metabolic tran-
sition to lower pyruvate results in a lower metabolic
state of the TCA cycle with age, we studied the
age-related shifts in metabolite levels of the TCA
cycle (Fig. 3). We first consider the inputs to the
TCA cycle from fatty acids, glutamine and branched
chain amino acids, followed by metabolites in the
cycle. Pyruvate enters the TCA cycle after conver-
sion into acetyl-CoA. Fatty acid -oxidation, also
produces acetyl-CoA (pink highlight in Fig. 3). With
age, acetyl-CoA levels increased 2 to 2.5-fold in
both genotypes and genders. With AD genetic load,
acetyl-CoA was 23% in females and 121% higher
in male 3xTg-AD old samples. This suggests an
increased production or a decreased consumption of
acetyl-CoA in the TCA cycle with age that was fur-
ther exacerbated with AD genetic load, indicating
higher demand for energy. Upstream of acetyl-CoA,
1.1–2.9-fold increased accumulation of fatty acids
with age is shown for two fatty acid-carnitine con-
jugates, butyryl-carnitine and propionylcarnitine.
Elevated glutamine
Other increased input to the TCA cycle occurs
from glutamine and branched chain amino acids
(BCAA). Glutamine feeds into the TCA cycle at the
level of -ketoglutarate (Fig. 3) and serves as an
important source of intermediary metabolites [43].
With aging, glutamine levels rose 7 to 27% for both
genotypes and genders (Fig. 4). Yet another metabo-
lite branch to -ketoglutarate, 2-hydroxyglutarate
levels increased 1.5 to 6.5-fold in 3xTg-AD com-
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Fig. 3. Age-related declines in the substrates of the TCA cycle from increased inputs at acetyl-CoA, succinyl carnitine, and fatty acid
metabolism. ns indicates detection but not significantly affected by age; ND, not detectable.
pared to NTg samples in both genders (p < 0.001).
However, -ketoglutarate levels changed little with
aging. The age- and AD-associated accumulation in
glutamine and 2-hydroxyglutarate levels without sig-
nificant change in -ketoglutarate levels indicates a
possible age- and AD-related blockage at the site of
-ketoglutarate for metabolic input to the TCA cycle.
Branched chain amino acids increased in
females
BCAAs include leucine, isoleucine, and valine.
Since BCAA are converted into acetyl or succinyl-
CoA in the TCA cycle for NADH and for eventual
ATP generation, we examined their changes with age,
genotype, and gender. Leucine, isoleucine, and valine
were1.2–1.3-fold higher in female samples than male
(p < 0.05). Changes with age or genotype were not
detected.
Decreased metabolites in TCA cycle
In the TCA cycle itself, metabolites decreased con-
siderably with age, including citrate, cis-aconitate in
both genders and succinate in males (green circles
and green arrows in Fig. 3). In females, citrate and
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Fig. 4. Age-related decreased glutamate metabolism from increased glutamine in both NTg and 3xTg-AD mice. Age drove decreases in
the levels of glutamate, NAA and NAAG, which suggests a lower input to -ketoglutarate in the TCA cycle or greater consumption. ns
indicates detection but not significantly affected by age; ND, no detectable. GLS: Glutaminase, GS: Glutamine synthetase, GAD: Glutamate
decarboxylase, GDH: Glutamate dehydrogenase
cis-aconitate dropped 46–47% in NTg and 30–35%
in 3xTg-AD with age. In males, age drove decreases
of citrate and cis-aconitate by 26–28% in NTg and
8–13% in 3xTg-AD. Succinate declined from middle
to old age by 25–28% in males of both genotypes,
but not in females. TCA cycle metabolites of the
3xTg-AD brains were generally lower than the age-
matched NTg mouse brains. Other metabolites in
the TCA cycle including -ketoglutarate, fumarate,
and malate were detected with little age-related
changes. Isocitrate, succinyl-CoA, and oxaloacetate
were not detected. In summary, the combination
of age-related increased inputs to the TCA cycle
together with decreased TCA cycle metabolites sug-
gests age-related limitations in utilization of the
inputs by the TCA cycle and consequent decreased
output of NADH with age and AD.
Age- and AD-associated redox pivot at
glutamate-α-ketoglutarate in glutamine
metabolism
In the glutamate-glutamine cycle, astrocytic
release of glutamine is transported into neurons to
synthesize neurotransmitters glutamate or GABA
and maintain glutamine/ glutamate pools [44] and
redox balance. Glutamate dehydrogenase (GDH)
catalyzes the interconversion of glutamate to -
ketoglutarate modulated by a redox sensitive site
depending on NAD+/NADH levels [45]. Depletion of
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glutamate-glutamine and gamma-aminobutyric acid
(GABA) were reported recently in normal aged
human brains and cognitively impaired patients by
magnetic resonance spectroscopy (MRS) [46]. These
metabolites feed into-ketoglutarate which functions
as a critical NAD+/NADH-dependent substrate in
the TCA cycle. We determined metabolic shifts in
glutamate with aging as an important upstream sub-
strate via GDH. Glutamine increased 7–27% with
age in both genotypes and genders (Fig. 4). Gluta-
mate levels declined 7% with age in males of both
genotypes, but female levels were unchanged (Fig. 4).
GABA as a major inhibitory transmitter in the brain
declined 14–16% with age in females of both NTg
and 3xTg-AD samples. N-acetylaspartyl glutamate
(NAAG) decreased 9–36% in both genders and N-
acetylaspartate (NAA) declined 10–23% with age
in males of both genotypes (Fig. 4). Given that the
brain levels of NAA correlate with cognitive func-
tion [47], the lower levels of NAAG and NAA may
contribute to cognitive impairments in age and AD.
Aspartate was detected with less significant shifts
with age of both genotypes in female (p = 0.12) and
male (p = 0.25) (figure not shown). Our results are
in accordance with decreased glutamate neurotrans-
mission in AD patients [48]. Taken together, these
shifts in glutamate metabolism with age may impair
neuronal transmission.
Increased fatty acid metabolites with age
During energetic shortage with lower glucose
intake or lower ATP generation via glycolysis and the
TCA cycle, fatty acids undergo-oxidation with pro-
duction of acetyl-CoA and NADH to power energy
production and maintain redox balance [49]. Carni-
tine is conjugated to fatty acids for transport into
mitochondria. Figure 3 shows that metabolites of
butyrylcarnitine (C4) and propionylcarnitine (C3) in
the short chain fatty acid pathway increased with
age 1.2–2.9-fold in female and 1.1–1.8-fold in male
as their dehydrogenase consumes NAD+ to provide
acetyl-CoA and NADH inputs. Compared to NTg,
in old age, the AD genetic load increased levels of
butyrylcarnitine (C4) 77% in female and 28% in male.
Other metabolites of carnitine metabolism including
carnitine and acetylcarnitine (C2) showed 1.5 to 2.5-
fold elevations with aging in both NTg and 3xTg-AD
samples (not shown, p < 0.05). To globally view fatty
acid metabolites, their direction and magnitude were
clustered to demonstrate a wide range of age-related
increases with both genotypes and genders (Fig. 5).
Each metabolite with a significant age-associated
(gender and genotype) shift by two-way ANOVA
is shown. After calculation of Euclidean distances
and clustering distances, the heatmap pattern showed
a strong age effect for upregulation of fatty acid
metabolism (x-axis). After clustering of the levels of
fatty acids, we observed a strong age effect that drove
2-fold elevations of fatty acids (Fig. 5). Further, AD
genetic load drove 21–22% more elevations of fatty
acid metabolism in old 3xTg-AD samples compared
to those of NTg for both female (p < 10−23) and male
(p < 10−17) samples. The age and AD upregulation in
fatty acid metabolism drove 1.8 to 2.6-fold elevations
of acetyl-CoA in old versus young neurons as a final
product of fatty acid -oxidation for entry into the
TCA cycle (Fig. 3). The global upregulation in fatty
acid metabolism with age suggests an age-related
demand for more energetically dense substrates than
carbohydrates to generate maximum NADH from
3-hydroxyacyl-CoA dehydrogenase or impairment
the TCA cycle to use the resulting CoA with aging
[50]. Furthermore, the greater upregulation in fatty
acid metabolism in 3xTg-AD old brains compared
to old NTg suggests a greater demand for energy
in the aged 3xTg-AD brains. Elevation of numer-
ous fatty acids with age and AD together with their
carnitine conjugates could supply energy by their
-oxidation.
Age- and AD-related lower expression in
sphingolipid metabolism in mouse brains
Sphingolipids play numerous functions in cells,
from structural components (sphingomyelins) to sig-
naling (ceramides, sphingosine-1-phosphate). Sph-
ingomyelins are important constituents of lipid
rafts, which are particularly enriched in the cen-
tral nervous system [51]. With age, sphinganine
decreased 31–42% (Fig. 6) and sphingomyelin
declined 14–29% with age of both genotypes and gen-
ders. Ceramides serve signaling functions, including
apoptosis and inflammation, which have been asso-
ciated with pathogenesis of AD [52]. In sphingolipid
metabolism, the downstream intermediates including
ceramide, sphingosine and sphingosine-1-phosphate
were increased 27–143% with age in 3xTg-AD male
brains (Fig. 6). The increased ceramides are consis-
tent with higher inflammation with age, especially in
the male AD genotype.
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Age-related metabolic shifts sensed at
NAD+/NADH redox reactions
Since we found age- and AD-related depletion
in the NAD pool size and free NADH levels in
mitochondria of hippocampal neurons from NTg and
3xTg-AD mouse brains [35] and an increased ratio
of NAD+/NADH indicating an oxidative shift in
these mice [34], we specifically examined metabolite
levels upstream and downstream of dehydrogenases
that sense the NAD+/NADH redox sites. Table 1
dichotomizes fold-changes with age in upstream
substrates of 9 dehydrogenases compared to their
downstream metabolites. Interestingly, in energy-
producing metabolic pathways, including glycolysis
and the TCA cycle, age drove decreased lev-
els of the upstream substrates of dehydrogenases
while downstream substrates increased in both
of NTg (T-test upstream versus downstream sub-
strates, p = 3 × 10−7, n = 8 reactions, 18 upstream
metabolites versus 10 downstream metabolites) and
3xTg-AD (T-test, p = 4 × 10−5). Glycolytic sub-
strates were markedly depleted upstream of GAPDH,
while GAPDH downstream products were enriched
2.7–2.8-fold, especially in female 3xTg-AD. Small
decrease in lactate in NTg product may indicate uti-
lization by neurons as described; small increase in
3xTg-AD may indicate failure to do so because of
susceptibility to acidosis [53]. In the TCA cycle,
KG was actually decreased, but only 1.1–1.2-
fold in 3xTg-AD. Overall, for NTg, age drove a
2.5-fold metabolic shift in the upstream versus down-
stream substrates of dehydrogenases and a slightly
lower with 2.3-fold metabolic shift in 3xTg-AD
samples (Table 1). These overall age-associated
effects on decreased upstream substrate levels with
increased downstream substrate levels suggests an
age-related rise in NAD+-dependent dehydrogenase
rates to make NADH with a decreased ability to
process the products leading to accumulated lev-
els of downstream metabolites. Other energy-redox
components were detected but showed less sig-
nificant changes with age, including coenzyme A
(CoA), flavin adenine dinucleotide (FAD), flavin
mononucleotide (FMN), and NAD (p≥ 0.05). Fur-
ther redox-controlled enzymatic measurements in
aging and 3xTg-AD mouse brains will need to be
completed for validation. In BCAA metabolism cat-
alyzed by branched-chain -ketoacid dehydrogenase
complex (BCKDH complex), the last step is to re-
oxidize FADH2 to FAD while reducing NAD+ to
NADH. BCKDH converts BCAAs into acyl-CoA
derivatives, which are converted into acetyl-CoA or
succinyl-CoA. Overall, we found age-related 2-fold
increases in acetyl-CoA for input into the TCA cycle
in hippocampal neurons from both NTg and 3xTg-
AD genotypes.
Based on our observations, we considered whether
age- and AD-associated oxidized in NAD+/NADH
redox potentials, triggered the metabolic shifts sensed
at the NAD+/NADH redox sites in the enzymatic
reactions and drove the direction for more NADH
and ATP generation as a compensatory effect in
response to the energetic deficits for NADH and ATP
replenishment. However, age- and AD-related oxi-
dized shifts impaired mitochondrial functions and
lower the activities in TCA cycle and ETC-OXPHOS
resulting in declines NADH production from the
TCA cycle and further leading to an energetic short-
age state with insufficient ATP levels. Supported
by our results, we observed dramatically upregu-
lated metabolic branches feeding into the TCA cycle
including fatty acid oxidation, BCAA metabolism,
and glutaminolysis. In contrast, the metabolite lev-
els in the TCA cycle decreased with aging and
AD. This suggests that either enzymatic rates were
lower with age in the TCA cycle or the ETC-
OXPHOS was impaired in mitochondria during aging
and AD.
DISCUSSION
In this work, we determined the age-, AD-,
and gender-associated global metabolomic shifts
of mouse hippocampal tissue by using untargeted
(unbiased) UPLC-MS/MS. We observed specific
metabolic features and patterns in age and AD mouse
brains including glycolysis, TCA cycle, glutamate
metabolism, fatty acid metabolism, and sphingolipid
metabolism, suggesting shifts in metabolic pathways.
Moreover, many of the metabolic shifts were com-
mon to both age and AD-genotype. Of note, our
results showed age-related deficiencies in energy-
generating pathways in glycolysis and the TCA
cycle. In the glycolysis-PPP pathways, we observed
declines in the first half of glycolysis involved in ATP
consumption and downstream intermediates in PPP.
Metabolites in the second half of glycolysis associ-
ated with ATP production were upregulated in old
age of both NTg and 3xTg-AD. As the detected
metabolic profiles in different ages, genotypes and
genders were steady-state snap shots, the metabo-
lite levels reflect net effects of upstream enzymatic
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Fig. 5. Elevated fatty acid metabolites cluster by age and genotype in both females and males. Scaled intensity of each metabolite in each
sample was clustered in rows and columns. Differences in levels were clustered predominantly by age. Genotype effects were remarkably
distinguished starting from middle age. Gender was less affected. Green indicates a lower scaled intensity and red indicates a higher scaled
intensity. tri, 3xTg-AD; non-tri, NTg; Y, young; M, middle-age; O, old, un-numbered; 1, 2, 3, 4 = sample number from different mice.
production and downstream enzymatic consumption.
We propose that these metabolic shifts serve not only
to maximize ATP production to meet increased age
and AD-related demand, but also serve to maintain
redox balance and maximize NADH production for
maximum generation of ATP from oxidative phos-
phorylation [14]. Interestingly, this energetic shift
occurs at the 9 NAD-dependent dehydrogenase steps
in glycolysis, the TCA cycle and inputs to the TCA
cycle that we feature in Table 1. We noticed remark-
able declines in substrates with increases in products
for both genotypes. This indicates that with age, dehy-
drogenases in old age neurons operate to consume
substrates at faster rates than that of younger ages
leading to age-related accumulations of downstream
products. This scenario is consistent with greater
energy demands with age. However, since the NAD
pool (NAD+NADH+NADP+NADPH) declines with
age systemically [54] and in our mouse brains
[34], NADH available for oxidative phosphoryla-
tion would also decline. We found that the free
NADH available in mitochondria declines with age
by 43% in the same NTg mouse hippocampal regions
and 50% with age in the 3xTg-AD [35]. Together,
these results suggest a critical NAD+/NADH role
in regulation of metabolism as a redox sensor in
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Fig. 6. Age-related changes in sphingolipid metabolism of both NTg and 3xTg-AD suggest increased inflammation. Age drove significant
declines in sphinganine and sphingomyelin (green ovals and arrows), but elevated the downstream metabolites of sphingolipid metabolism,
including ceramide, sphingosine and sphingosine-1P in both NTg and 3xTg-AD female and male samples (red ovals and arrows). ns indicates
detection but not significantly affected by age; ND, no detectable.
aging and AD. The age- and AD-related deple-
tion on NAD and NADH pool sizes may limit the
activities of dehydrogenases, metabolic shifts and
ATP production. Besides, the age- and AD-related
energy deficits, we observed enhanced input to the
PPP pathway with lower downstream intermediates
with age. This suggests a response to oxidative
stress in age and AD brains that causes a rise in
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Table 1
Age-related metabolic shifts in upstream and downstream of redox dehydrogenases (fold change with age)
Upstream Substrate NTg 3xTg-AD Downstream Product NTg 3xTg-AD
F M Avg. F M Avg. F M Avg. F M Avg.
Glycolysis
GAPDH G6P –2 –1.7 –1.6 –1.4 3PG 1.6 2 2.8 1.9
F6P –2 –1.6 –1.4 –1.4 PEP 1.7 2 2.7 1.9
DHAP –1.2 –1.1 1.2 –1.3 *c
LDH Pyruvate –1.8 –1.4 –2 –2.4 lactate –1.08 *b 1.15 *b
Avg.(F + M) –1.60 –1.29 Avg.(F + M) 1.24 2.09
S.E. 0.13 0.41 S.E. 0.66 0.34
N= 8 8 N= 5 5
TCA cycle
PDH Pyruvate –1.8 –1.4 –2 –2.4 Acetyl-CoA 1.8 2.6 2.5 2.3
IDH Cis-aconitate –1.9 –1.4 –1.4 –1.1 a-KG 1.17 –1.1 –1.08 –1.2
GDH Glutamate *b –1.1 *b –1.1 *c
KGDHC a-KG 1.17 –1.1 –1.08 –1.2 ND
SDH Succinate –1.1 –1.4 *a –1.2 –1.3 *a Fumarate *b 1.4 –1.2 –1.3
MDH Malate *b –1.1 *b –1.1 ND
Avg.(F + M) –1.11 –1.39 Avg.(F + M) 1.17 0.0033
S.E. 0.28 0.15 S.E. 0.69 0.83
N= 10 10 N= 5 6
Total Effect
Avg.(F + M) –1.33 –1.34 Avg.(F + M) 1.21 0.95
S.E. 0.17 0.19 S.E. 0.42 0.56
N= 18 18 N= 10 11
T-test (Up versus Down)
NTg 3xTg
p value 3E-07 4E-05
Fold change (FC) with age = larger values / smaller values in young versus old measurements. *a, middle-age versus old; *b, missing
value ratio was 1.0, which could not be assigned a negative or positive direction; *c, metabolites already listed. “+” indicates metabolite
levels increased with age; “–” indicates metabolite level decreased with age. GAPDH, glyceraldehyde 3-phosphatedehydrogenase; LDH,
lactate dehydrogenase; PDH, pyruvate dehydrogenase; IDH, isocitrate dehydrogenase; GDH, glutamate dehydrogenase; KGDHC, alpha-
ketoglutarate-dehydrogenase complex; SDH, succinate dehydrogenase; F, female; M, male.
PPP with more NADPH production for antioxidant
defense. Perturbations in glutamate and sphingolipid
metabolisms suggested age- and AD-related impair-
ments at synapses and in myelinated axons involved
with memory.
Glycolysis and the TCA cycle
Compared to non-demented controls, positron
emission tomography with 2-deoxy-2-[fluorine-18]-
D-glucose (18F-FDG PET) in AD patients exhibit
a metabolic pattern of bilateral temporo-parietal
hypometabolism [55] and reduced blood flow [56].
We observed greater age- and AD-associated declines
of glucose levels in hippocampal regions in females.
Altered glucose levels were the net effects of
a failure to increase glucose uptake under stress
[57] and consumption in the downstream metabolic
pathways including the glycolysis-PPP pathway.
Further, we found aging dramatically upregulated
intermediates in glycolytic steps of ATP produc-
tion including 3-phosphoglycerate and phosphoenol
pyruvate. Moreover, AD genetic load drove increases
two-fold higher than the age-matched NTg male sam-
ples. Downstream of the NAD+-dependent GAPDH,
pyruvate levels decreased as much as 2-fold, espe-
cially in the 3xTg-AD samples. Administration of
pyruvate prevented the development of age-related
cognitive impairments in 3xTg-AD mouse brains
without reducing AD pathologies of amyloid and tau
[58]. Pyruvate as the end metabolite in glycolysis is
transported into mitochondria via the mitochondrial
pyruvate carrier. Inhibition of mitochondrial pyruvate
carrier was reported to diminish the neurodegen-
eration in Parkinson’s disease by augmentation of
autophagy [59, 60]. The TCA cycle plays a central
role in glucose metabolism with multiple points of
influx at different intermediate sites, such as fatty acid
-oxidation via acetyl-CoA, BCCA catabolism via
succinyl-CoA, and glutamine-glutamate metabolism
via -ketoglutarate, aspartate, and phenylalanine. In
AD patients, mitochondrial abnormalities are associ-
ated with decreases of enzymatic activity in the first
half of the TCA cycle, including pyruvate dehydroge-
nase, isocitrate dehydrogenase, and -ketoglutarate
dehydrogenase (KGDHC) [1], but an age-related
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basis for these changes has not been determined and
their fluxes in vivo depend on substrate and prod-
uct concentrations. When the thiamine-dependent
KGDHC was deprived of thiamine in an AD mouse
model, mitochondrial KGDHC activity decreased
43% and promoted early formation of plaques and
tangles [61]. Activity of cytochrome c oxidase
decreased by 50% with age from 3 to 12 months
in 3xTg-AD female mouse brain and PDH activity
declined by 55% [62]. PDH activity in brain mito-
chondria was also found to be decreased by 25% and
45% in mitochondria from 14- and 24-month-old rat
brains [63]. In our results, we observed up to 2-fold
declines in pyruvate levels with age, worse in the
AD-genotype, followed by 2-fold increases of acetyl-
CoA with higher levels in the 3xTg-AD. Nearly 60%
of nuclear genes encoding subunits of mitochondrial
electron transport chain showed significantly lower
expression in hippocampal CA1 of human AD cases
brains [64]. Together, these results suggest that dur-
ing aging and AD, the lower activity of the TCA cycle
may indicate a metabolic-energy blockage to power
ATP generation in the ETC-OXPHOS pathways.
Inputs to the TCA cycle
Among those metabolites that provide influx into
the TCA cycle, fatty acids for -oxidation and glu-
tamine were upregulated with age and AD, possibly
indicating a cellular need for maximizing generation
of energy. The downregulated intermediates with age
and AD in the TCA cycle together with accumulated
inputs to TCA cycle suggest a lower capacity for load-
driven demand for NADH to make ATP via the TCA
cycle-OXPHOS pathways. A neuron energy crisis
with reduced ATP synthesis can cascade into ionic
pump dysfunction [65], signal transduction break-
down [66], neurotransmitter failure [67], increased
cleavage of the amyloid- protein precursor [68],
microtubule damage [69], tau hyperphosphoryla-
tion [70], which all promote neurodegeneration and
region-specific neuroglial death [71]. Together with
the observation of “mitochondria-on-a-string” due
to mitochondrial fission in 5 transgenic AD mouse
models and brain tissue of AD patients [72] and
decreased free NADH levels with age and AD in
3xTg-AD brains [35], these results are consistent
with the hypothesis that age-related mitochondrial
metabolic deficits pivoting at NAD+/NADH redox
sensitive sites contribute to the systematic complexity
of brain aging and AD.
FA oxidation
Redox steps in fatty acid -oxidation first involve
oxidation by FAD in acyl-CoA dehydrogenase fol-
lowed by an oxidation by NAD+ in 3-hydroxyacyl-
CoA dehydrogenase inside mitochondria [73]. An
age-related oxidized NAD+/NADH redox state pro-
mote FA oxidation by converting NAD+ to NADH
and FAD into FADH2. We observed a 2-fold eleva-
tion in FA oxidation with aging in NTg and 3xTg-AD
mouse brains, suggesting that fatty acid -oxidation
may be driven by an oxidized redox state with aging.
In each cycle of oxidation, two carbons are cleaved
from a fatty acid to release acetyl-CoA. During
the last step of each FA oxidation cycle, thiolase
cleaves between the C2 and C3 of 3-ketoacyl-CoA
to release two carbons as acetyl-CoA. The gener-
ated acetyl-CoA enters the TCA cycle for more
NADH production to power OXPHOS and the gener-
ation of ATP. Interestingly, the thiolase that catalyzes
two acetyl-CoA molecules to form acetoacetyl-CoA
in Clostridium has a regulatory redox-switch [74].
The increased acetyl-CoA with age indicates excess
production that does not enter into the TCA cycle
stoichiometrically and is not used as much with age
by Sirtuins or other acetylations. As the redox poten-
tial of NAD+/NADH is oxidized with aging and AD,
this could drive the direction of FA oxidation reac-
tions for more acetyl-CoA production. The age- and
AD- related increased fatty acid -oxidation and ele-
vated production of acetyl-CoA could be a metabolic
response to lessen energetic shortages. Adiponectin
secreted by adipocytes plays an important role in
stimulating glucose utilization and fatty acid oxi-
dation via activation of 5’-AMP-activated protein
kinase, suggesting a novel intervention to regulate
glucose and fatty acid metabolism [75]. Efforts to ele-
vate acetyl-CoA by overexpression of AT-1 in mice
results in a progeria phenotype [76], suggesting that
raising acetyl-CoA is limited or outright pathologic.
Moreover, disturbances of fatty acid metabolism
and increased in polyunsaturated fatty acids in age
and AD brains is associated with upregulation of
inflammatory signaling in neurodegenerative dis-
eases [77]. Increased polyunsaturated fatty acids
provide prostaglandins, leukotrienes, and thrombox-
anes, which increase inflammatory signaling [78],
further promoting neurodegenerative processes. An
mRNA microarray study on 759 innate immune
genes, from human brains with AD and normal cog-
nitive controls, revealed widespread upregulation of
genes associated with inflammation in human aging
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correlated to cognitive declines [79]. Another study
found elevated blood levels of fatty acids in MCI
prognostic for conversion to AD [80].
Branched chain amino acids
Although we did not find age-related hippocam-
pal changes in isoleucine, leucine, or valine, their
oxidation by NAD+ in the BCKDH complex pro-
duces NADH, to maintain redox balance and feed
OXPHOS. Increased BCAA metabolites in human
plasma such as isoleucine are positively correlated
with AD [81]. BCAAs are elevated with age in serum
of human AD and 3xTg-AD mice [82]. The important
question is whether this is protective or pathologic. In
the 3xTg-AD mouse fed with a BCAA-supplemented
high-fat diet for 2 months, tau and amyloid patholo-
gies worsened leading to an increase in the mortality
of two-thirds of the mice from 6 to 16 months [83].
This intervention suggests that BCAA and fatty acids
are not limiting to energy production and that excess
levels are pathologic, but systemic stress could also
be important, independent of brain metabolism. Con-
versely, a low BCAA diet was found to improve
recognition memory in 18-month-old 3xTg-AD mice
[83]. Taken together, the BCAA metabolites levels in
plasma may serve as a biomarker for an AD metabolic
switch and pathology.
Lactate
Our results showed remarkable increases in the
ratio of lactate/pyruvate levels as a function of age
in both NTg and 3xTg-AD mouse brains. Notably,
declines in pyruvate with small changes in lactate
levels with aging and AD, indicate a balance of rates
between production of lactate by LDH and the rates
of either utilization or removal into blood. Alterna-
tive energy supplies were found to be upregulated in
age and AD brains, such as lactate [84] and ketone
bodies (KB) [24]. Lactate increased 1.5-fold in AD
patient serum compared to the healthy control sub-
jects [85]. CSF lactate levels in AD patients increased
20% compared to age-matched controls [86]. Lactate
increased two-fold with age in mtDNA mutator mice
with a metabolic shift from pyruvate to more lac-
tate production [87]. Lactate is a preferred energy
substrate to maintain redox balance and neuronal
activity especially during glucose deprivation [84].
Memory in rats was dependent on neuronal import
of lactate from astrocytes via the monocarboxylate
transporter [88]. Astrocyte-neuron lactate transport
is critical for long-term memory formation [89]. In
aging wild-type mouse brains, improved memory
performance correlated with elevated expression of
glycolytic enzymes. Yet this age-related increase in
glycolytic enzyme expression with elevated lactate
levels in APP/PS1 mice were associated with poorer
memory performance [90]. Again, whether the age-
and AD-correlated alterations in lactate levels play
a rescue role to release the energetic deficits or in
turn to exacerbate the AD pathologies needs to be
further investigated. Our failure to detect significant
changes in lactate in the hippocampus with age sug-
gests though lactate may be an alternative energy
source during age-related energetic shortage, it did
not accumulate in old age NTg or 3xTg-AD hip-
pocampus, likely by increased activity of LDH to
maintain redox balance [14].
Ketone bodies as another alternative energetic
source
In our results, we observed an age-related 40–55%
decline in the levels of 3-hydroxybutyrate in the
3xTg-AD samples of both genders (p < 0.05), indi-
cating a possible higher utilization of KB as an
energetic source in aging and AD brains. KB are
another alternative energy substrate, which derive
from the incomplete oxidation of fatty acids in the
liver. Three KB including acetone, acetoacetate, and
-hydroxybutyrate are interconvertible and metabo-
lized to succinyl-CoA feeding into the TCA cycle
with generation of NADH for energy production
during energetic demand [91, 92]. As administra-
tion of KB can bypass the AD-related blockage
in PDH and insulin resistance and provide needed
NADH for redox balance, mild ketosis provides a
potential therapy for AD [93]. Diet supplementa-
tion with pyruvate (5 mM) and -hydroxybutyrate
(4 mM) for 5 weeks showed diminished neuronal
hyper-excitability in 3xTg-AD mice [94, 95]. Com-
pared to normal levels of KB less than 0.1 mM in
blood and pathological ketoacidosis of 15–25 mM,
nutritional ketosis from a low-carbohydrate- high-fat
diet raised blood KB to 7-8 mM and reduced total A
loads in a mouse model of AD [96, 97]. Importantly,
nutritional ketosis increases NAD+/NADH redox
states in young healthy human brains [98]. Even
though ketones cannot completely replace glucose
for energy source, mild experimental ketonemia in
rats improves brain glucose uptake [99, 100], proba-
bly by improved redox balance. In another AD mouse
model, a ketogenic diet reduced total A40 and A42
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pathologic load [101]. The expression of monocar-
boxylate transporters for transporting lactate and KB
increased in female brains at 12 months in NTg but
earlier at 3-month in 3xTg-AD, indicating the acti-
vation of the ketogenic pathway [24]. Our data of an
age-dependent decline in 3-hydroxybutyrate levels in
3xTg-AD hippocampus adds to the above findings to
suggest that a therapeutic ketogenic diet may supply
extra NADH reductive energy and maximize genera-
tion of energy. However, further studies are needed to
uncover the mechanism of potential beneficial effect
of dietary KB considering the contradictory roles of
ketosis on anorexigenic and orexigenic signals [97].
Glutamate
In our NTg and 3xTg-AD mouse model, glutamate,
GABA, NAAG, and NAA markedly declined with
age, suggesting decreased availability of synaptic
neurotransmitters. NMDA receptors rely on gluta-
mate to induce hippocampal long-term potentiation
of synapses for learning and memory [102, 103]. As
glutamine functions as a cellular energy source, the
age-related elevations in glutamine suggest increased
energetic demand in aged brains. In Fig. 4, age-related
declines in glutamate with increased glutamine may
be due to more consumption of glutamate. Decreased
levels of glutamate [104], NAAG, and NAA are asso-
ciated with disorders of learning and memory [105]
and pathogenesis of AD [106]. Glutamatergic neuro-
transmission in hippocampus is severely disrupted in
AD [107, 108]. The decline in neurotransmitters with
age could be a response to decreased energy available
to maintain ionic homeostasis associated with neuro-
transmission and feedback to reduce excitotoxicity.
Sphingolipids
Our results of age- and AD-related patterns
of upregulation of ceramide and sphingosine-1-
phosphate suggest increased inflammation with age
and AD. Sphingolipid metabolism is deregulated in
AD brains with a pattern of elevated acid sphin-
gomyelinase and acid ceramidase expression [109].
Elevated ceramides and sphingosine-1-phosphate
as signaling molecules correlate with inflamma-
tion [110]. Since the oxidized redox potentials of
Cys/CySS in human plasma were positively core-
lated with interleukin-1 levels [111], our results of
an oxidative shift with age in neurons (Dong, Digman,
Brewer, unpublished data) could promote inflamma-
tion. Additionally, sphingolipids mediate synaptic
plasticity [112], and disturbances in sphingolipid
content correlated with impairment in memory and
learning [113]. Studies of 30 human plasma samples
from each group of AD, MCI, and normal control sub-
jects revealed remarkable declines in sphingomyelin,
especially in females [114].
Conclusions
According to the epigenetic oxidative redox
shift aging theory [14], we hypothesized that an
age-associated sedentary behavior triggers oxida-
tive shifts and mitochondrial impairments, which
cause downstream cascades. To offset the age-related
energetic deficits, redox-sensitive epigenetic modi-
fication enforces metabolic shifts in aging brains.
Here, we found evidence for a metabolic pivot
at redox-dependent bioenergetic enzymes that gen-
erate NADH. Age- and AD-associated oxidized
NAD+/NADH redox states (increased ratio) [34,
35, 115, 116] could signal metabolic re-direction
for more NADH generation by epigenetics, redox-
sensitive transcription factors [117, 118], redox
sensing cysteines in the enzyme [119], nitration
of KGDHC [120], acylation of KGDHC [121], or
NAD+/NADH substrate limitations [122]. However,
lower levels of metabolites in the TCA cycle sug-
gests a limitation or blockage at the TCA cycle,
depriving the ETC-OXPHOS of NADH for ATP
generation [1]. The NAD+/NADH redox couple is
likely to function as a sensor for dehydrogenases at
the pivot of upstream and downstream metabolites
in pathways including glycolysis, the TCA cycle,
fatty acid oxidation and BCAA metabolism. The age-
and AD-related oxidative shifts with drops of NAD
pool size are sensed by NADH redox sites in the
metabolic pathways and serve as a switch to affect
the rate or direction of metabolic flux. Taken together
with the age- and AD-associated energetic short-
age, metabolic upregulation in fatty acid metabolism
likely generates NADH as an alternative to carbo-
hydrate oxidation to maintain redox balance and
maximize energetic capacity.
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